本帖最后由 老马 于 2013-3-13 13:43 编辑 / f# J+ r U/ e7 ]2 U
7 v" S5 b" t' b/ W
健择（吉西他滨）+顺铂+阿瓦斯汀
# F' ~0 P1 g' k) V9 U" P3 I* Z! K) A& D Gemzar +Cisplatin + Avastin
6 [& _" ?! c% j7 h* {1 Qhttp://annonc.oxfordjournals.org/content/21/9/1804.full# N+ c4 v$ P$ G
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
/ J: h! l3 D0 h6 q5 Y4 e* F) mPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 9 U8 F _& H( u F0 B3 q- f1 s* D
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ; I+ G$ m# t5 M- f# |% e- R* f& u
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 557)
) P7 p( h* b" Y4 M! W
华为网盘附件：$ D4 w* n) V. P& n# I' ^* n% |
【华为网盘】ava.JPG$ h0 u+ k. a- ^0 q3 I
|
显身卡
